Back to Search
Start Over
Astellas Pharma announces positive results from phase 3b trial of fezolinetant to treat VMS due to menopause
- Source :
- PharmaBiz. June 29, 2023
- Publication Year :
- 2023
-
Abstract
- Astellas Pharma Inc. announced positive topline results from the phase 3b DAYLIGHT clinical trial for fezolinetant, an investigational oral, nonhormonal compound being studied for the treatment of moderate to severe [...]
Details
- Language :
- English
- Database :
- Gale General OneFile
- Journal :
- PharmaBiz
- Publication Type :
- Periodical
- Accession number :
- edsgcl.755124759